Liau M C, Szopa M, Burzynski B, Burzynski S R
Drugs Exp Clin Res. 1987;13 Suppl 1:61-70.
Plasma and urinary peptides can be reproducibly assayed by a procedure involving reverse phase chromatography on a column of C18 and HPLC on a column of sulfonated polystyrene. The average plasma and urinary peptide levels of normal persons are 79.4 nmoles/ml and 73.6 nmoles/mg creatinine, respectively. Ninety-one percent of 108 confirmed cancer patients referred to the authors' Clinic for antineoplaston therapy showed various degrees of deficiency of peptides in the plasma, and 98% of the patients had plasma/urine peptide ratios below the normal ranges of 0.82 to 1.15, indicating that the overwhelming majority of cancer patients excreted greater than normal amounts of peptides in the urine. When a patient responded favourably to the antineoplaston therapy, the excessive urinary excretion of peptides was reversed. Plasma levels of peptides and plasma/urine peptide ratios showed a steady increase after one to two months and eventually approached those of normal persons. On the other hand, if a patient was not responding to the antineoplaston therapy, the excessive urinary excretion of peptides remained unaltered or even became greater. Patients in remission following antineoplaston therapy tended to show plasma and urinary peptide levels comparable to those of normal persons. Thus the quantitative assay of plasma and urinary peptides provides a useful parameter for the evaluation and prognosis of cancer patients undergoing antineoplaston therapy. A growing colon tumour was found to have the lowest level of peptides among mice tissues analysed, suggesting that deficiency of inhibitory peptide components may be associated with malignant growth. The results of this study are consistent with the interpretation that a deficiency of antineoplastons may be required for malignant cells to proliferate, and the consequent malignant growth further aggravates this deficiency. Antineoplaston therapy can halt such a "vicious cycle" and induce long-term remission in some cancer patients.
血浆和尿肽可以通过一种涉及在C18柱上进行反相色谱以及在磺化聚苯乙烯柱上进行高效液相色谱的方法进行可重复测定。正常人的平均血浆和尿肽水平分别为79.4纳摩尔/毫升和73.6纳摩尔/毫克肌酐。转至作者诊所接受抗肿瘤药治疗的108例确诊癌症患者中，91%的患者血浆中肽存在不同程度的缺乏，98%的患者血浆/尿肽比值低于0.82至1.15的正常范围，这表明绝大多数癌症患者尿中肽的排泄量高于正常水平。当患者对抗肿瘤药治疗反应良好时，尿中肽的过量排泄会逆转。肽的血浆水平和血浆/尿肽比值在一到两个月后稳步上升，最终接近正常人水平。另一方面，如果患者对抗肿瘤药治疗无反应，尿中肽的过量排泄保持不变甚至增加。接受抗肿瘤药治疗后缓解的患者血浆和尿肽水平往往与正常人相当。因此，血浆和尿肽的定量测定为接受抗肿瘤药治疗的癌症患者的评估和预后提供了一个有用的参数。在分析的小鼠组织中，发现生长中的结肠肿瘤肽水平最低，这表明抑制性肽成分的缺乏可能与恶性生长有关。本研究结果与以下解释一致，即恶性细胞增殖可能需要抗肿瘤药缺乏，而随之而来的恶性生长会进一步加剧这种缺乏。抗肿瘤药治疗可以阻止这种“恶性循环”，并使一些癌症患者实现长期缓解。
